Novavax plans to file for FDA approvals in the third quarter for its COVID-19 vaccine NVX-CoV2373, after it showed 90.4% overall efficacy, and 93% efficacy against the five most prevalent SARS-CoV-2 variants “of concern” and eight more variants “of interest,” in a Phase III trial.
SCG says it has developed in-house cGMP manufacturing capabilities to supply high-quality cell therapy products to patients.
And there are benefits of plant cell expression systems, notably their impact on the cost of goods sold (COGS).
A British-based cell therapy company is using smart operations to streamline its viral vector processing.
CMS proposed Medicare’s CGT reimbursement policy matches Medicaid’s sickle cell disease policy, forming a unified government approach.
Prodigiosin applications extend from manufacturing pigment and environmental-control agent to antibiotic and potential oncology drug.
Insilico Medicine is heading to the clinic with a treatment for methylthioadenosine phosphorylase (MTAP) deleted cancers.
New data-intensive platforms continue to leverage artificial intelligence tools for improved speed and failure rate reductions for drug discovery.
The mini colons replicate both the physical structure and cellular diversity in the colon in both healthy and diseased states.
Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
Workflow design and data management are pivotal components of cell and gene therapy research and development. Advances in artificial intelligence, informatics, and automation have made…
